Oramed Pharmaceuticals Inc. — Director's Dealing 2023

Apr 20, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ORAMED PHARMACEUTICALS INC. (ORMP)
CIK: 0001176309
Period of Report: 2023-04-17

Reporting Person: Kidron Miriam (Director, Chief Scientific Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-04-17	Common Stock	A	213000	—	Acquired	414666	Direct

Footnotes

F1: Represents Restricted Stock Units ("RSUs") that will vest in equal quarterly installments of 17,750 over a three year period starting May 1, 2023. The RSUs convert into the Issuer's Common Stock on a one-for-one basis.